VYNE had a favorable earnings report last week. Fundamentally, analysts predict ( linked) approximately a doubling of the shart price in the next year. Like many low share priced biotechnology stocks the price is based on perceived future earnings which can be affected by favorable FDA process, or well-received research at industry conferences and changing...
Since VYNE Therapeutics has enough cash (148m) for 2021 and even into 2022 (possible to turn profitable in 2021), they have a stable cash burn rate. Indicates their financials are strong. Break-even reaches 8500 prescriptions a week / 25 million quarter. Furthermore, with two approved FDA drugs commercialized (AMZEEQ and ZILXI covered by three major PBMS,...
Not a financial advice. Do your own research and have a happy trading. - the price is in decline both on h4 and daily - on H1 it starts to climb, a channel has formed that coincides with a support
I recently discovered VYNE - Not sure how, but what made me interested in investing in this stock was their potential to help individuals with severe acne, and based on the technical aspect of bottom formed curve and "break out" from its consolidation period, I felt it was a good thought to get into this company. It might actually become my future pension fund....